Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

Study of Safety and PK of AZD0543 in Healthy Adults

AstraZeneca · NCT07824622

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
144
US sites recruiting
1
Study start
August 31, 2026
Record last updated
September 17, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to assess the safety and PK of AZD0543 compared to placebo in healthy adults 18 to 55 years of age. AZD0543 or placebo will be administered as single IM or IV dose. The study duration will be approximately 12 months for each participant following administration of IMP.

Being studied: AZD0543; Placebo

Conditions: Human Metapneumovirus Infection

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Age 18 to 55 years
  • Body weight ≥ 45 kg and ≤ 110 kg and BMI within the range ≥ 18.0 kg/m2 to ≤ 30 kg/m2

Key Exclusion Criteria

  • Hypersensitivity to IMP/components
  • Severe adverse reaction/hypersensitivity to other mAbs
  • Acute fever/illness/infection within 3 days of planned dosing
  • Clinically important illness/procedure/trauma within 4 weeks of IMP administration
  • Active infection with Hepatitis B/C
  • Clinically significant bleeding disorders
  • Known/suspected immune deficiency/suppression
  • Receipt of blood products/immunoglobulins or immunosuppressive therapies within 6 months prior to screening (immunosuppressive medications/therapies include glucocorticoids exceeding 2 weeks of prednisone (or equivalent) 20mg daily or every other day)
  • Malignancy within previous 5 years; except treated non-melanoma skin cancers and locally treated cervical cancer
  • Receipt of any licensed/investigational hMPV vaccine, other therapies and procedures as applicable; participation in other clinical studies
  • Screening Abnormalities: clinically significant ECG, positive drug panel, Hgb/platelets/WBC outside of reference; all SCr/AST/ALT > 1.5X ULN
  • Women who are pregnant, lactating, or of childbearing potential and not using a highly effective birth control method

Recruiting US locations

Study contacts (from the official record)

  • AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
All healthy volunteers studies in Florida →
Study of Safety and PK of AZD0543 in Healthy Adults (NCT07824622) | Bored Studies